USD
+$0.00
(+0.00%
)At Close (As of Oct 16, 2025)
$268.57M
Market Cap
-
P/E Ratio
-1.81
EPS
$15.67
52 Week High
$4.05
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $81M |
Total Revenue | $137M |
Cost Of Revenue | $54M |
Costof Goods And Services Sold | $54M |
Operating Income | -$53M |
Selling General And Administrative | $105M |
Research And Development | $31M |
Operating Expenses | $136M |
Investment Income Net | - |
Net Interest Income | $15M |
Interest Income | $15M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8.4M |
Income Before Tax | -$38M |
Income Tax Expense | $434K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$39M |
Comprehensive Income Net Of Tax | - |
Ebit | -$53M |
Ebitda | -$44M |
Net Income | -$39M |
Field | Value (USD) |
---|---|
Total Assets | $407M |
Total Current Assets | $364M |
Cash And Cash Equivalents At Carrying Value | $57M |
Cash And Short Term Investments | $57M |
Inventory | $33M |
Current Net Receivables | $32M |
Total Non Current Assets | $43M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $4M |
Intangible Assets Excluding Goodwill | $4M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $232M |
Other Current Assets | $9.6M |
Other Non Current Assets | - |
Total Liabilities | $76M |
Total Current Liabilities | $42M |
Current Accounts Payable | $7M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $9.5M |
Total Non Current Liabilities | $34M |
Capital Lease Obligations | $37M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $37M |
Other Current Liabilities | $16M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $330M |
Treasury Stock | - |
Retained Earnings | -$470M |
Common Stock | $39K |
Common Stock Shares Outstanding | $38M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$35M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $8.4M |
Capital Expenditures | $3.4M |
Change In Receivables | - |
Change In Inventory | -$6.7M |
Profit Loss | - |
Cashflow From Investment | -$82M |
Cashflow From Financing | $456K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$39M |
Field | Value (USD) |
---|---|
Gross Profit | $81M |
Total Revenue | $137M |
Cost Of Revenue | $54M |
Costof Goods And Services Sold | $54M |
Operating Income | -$53M |
Selling General And Administrative | $105M |
Research And Development | $31M |
Operating Expenses | $136M |
Investment Income Net | - |
Net Interest Income | $15M |
Interest Income | $15M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8.4M |
Income Before Tax | -$38M |
Income Tax Expense | $434K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$39M |
Comprehensive Income Net Of Tax | - |
Ebit | -$53M |
Ebitda | -$44M |
Net Income | -$39M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Quanterix Corporation is a leading life sciences innovator based in Billerica, Massachusetts, focused on revolutionizing precision health through its advanced digital immunoassay platforms. The company's proprietary technology allows for ultra-sensitive biomarker detection, empowering research and diagnostics in a variety of therapeutic areas and driving advancements in disease understanding and personalized patient care. With a strong global presence across North America, Europe, the Middle East, Africa, and Asia Pacific, Quanterix is positioned as a key player in the healthcare and diagnostics sector, committed to transforming patient outcomes and driving innovation in life sciences.